Istradefylline (KW-6002)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sleep Disorder

Conditions

Sleep Disorder, Restless Legs Syndrome

Trial Timeline

Jul 1, 2005 → Oct 1, 2006

About Istradefylline (KW-6002)

Istradefylline (KW-6002) is a phase 2 stage product being developed by Kyowa Kirin for Sleep Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00199446. Target conditions include Sleep Disorder, Restless Legs Syndrome.

What happened to similar drugs?

20 of 20 similar drugs in Sleep Disorder were approved

Approved (20) Terminated (2) Active (0)
Zolpidem MR + EstazolamAstellas PharmaApproved
Zolpidem MR + Zolpidem IRAstellas PharmaApproved
Lemborexant + PlaceboEisaiApproved
Eszopiclone + Placebo controlSumitomo PharmaApproved
Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved
Lunesta + Placebo controlSumitomo PharmaApproved
LunestaSumitomo PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT00250393Phase 2Completed
NCT00199446Phase 2Completed
NCT00199433Phase 2Completed
NCT00199355Phase 2Completed
NCT00199394Phase 3Completed
NCT00199420Phase 3Completed
NCT00199407Phase 3Completed
NCT00456794Phase 2Completed